


**CLAIMS**

1.- The use of a compound of formula I:



FORMULA I

wherein:

$n$  is 0, 1, 2, or 3


the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds;

$R$ , and  $R'$  are independently selected from hydrogen, alkyl, aryl,  $-OH$ ,  $-OR''$ ,  $-SH$ ,  $-SR''$ ,  $-NH_2$ ,  $-NHR''$ ,  $=O$ ,  $=NH$ ,  $=NR''$ ;

$R''$  is independently selected from alkyl, aryl,

in the preparation of a medicament for the treatment of a disease requiring a GSK-3 inhibitor.


2.- Use according to claim 1, wherein the compound of formula I is a compound of formula II:



FORMULA II


3.- Use according to claim 1, wherein the compound of formula I is compound

1:



Compound 1

4.- Use according to any one of claims 1 or 2, wherein the compound of formula I is compound 2:




Compound 2.

5. The use according to any one of claims 1 to 4, wherein the disease is Alzheimer's disease, or a tauopathy (Corticobasal degeneration, Pick's disease, supranuclear palsy, etc), bipolar disorder, diabetes type II, hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis, or chronic inflammatory process.

6. The use according to any one of claims 1 to 4, wherein the disease is a chronic neurodegenerative condition including dementias such as Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, guam parkinsonism-dementia complex, taupathies such as Pick's disease, corticobasal degeneration, supranuclear palsy, etc, frontotemporal dementia, Huntington's disease, AIDS associated

dementia, amyotrophic lateral sclerosis, multiple sclerosis, , diabetes, especially diabetes type II, and conditions associated with diabetes, neurotraumatic diseases such as acute stroke, mood disorders such as schizophrenia and bipolar disorders, promotion of functional recovery post stroke, cerebral bleeding (for example, due to solitary cerebral amyloid angiopathy), hair loss, obesity, atherosclerotic cardiovascular disease, hypertension, polycystic ovary syndrome, syndrome X, ischaemia, traumatic brain injury, cancer, leukopenia, Down's syndrome, Lewy body disease, cancer and hyperproliferative diseases as hyperplasias, metaplasias, displasias and immunodeficiency , psoriasis, arteriosclerosis or restenosis; and inflammation and chronic inflammatory processes.

7.- A compound of formula II:




FORMULA II

wherein


$n$  is 0, 1, 2, or 3

the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds.

8.- A compound according to claim 7, wherein the compound of formula II is compound 2:




9.- A compound of formula II:



FORMULA II

for therapeutic use.


10.- A compound of formula 2



Compound 2

for therapeutic use

11.- A pharmaceutical composition for use as a GSK-3 inhibitor comprising a compound of the formula:



FORMULA I

wherein:

$n$  is 0, 1, 2, or 3


the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds;

$R$ , and  $R'$  are independently selected from hydrogen, alkyl, aryl,  $-OH$ ,  $-OR''$ ,  $-SH$ ,  $-SR''$ ,  $-NH_2$ ,  $-NHR''$ ,  $=O$ ,  $=NH$ ,  $=NR''$ ;

$R''$  is independently selected from alkyl, aryl,


together with a pharmaceutically acceptable carrier.

12.- A pharmaceutical composition according to claim 11, wherein the compound of formula I is a compound of formula II:




FORMULA II

13.- A pharmaceutical composition according to claim 11, wherein the compound of formula I is compound 1:




Compound 1

14.- A pharmaceutical composition according to any one of claims 11 and 12, wherein the compound of formula I is compound 2:



Compound 2.

15.- A method of treating Alzheimer's disease, or a tauopathy (Corticobasal degeneration, Pick's disease, supranuclear palsy, etc), bipolar disorder, diabetes type II, hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis, or chronic inflammatory process, which comprises administering a compound of formula I:



FORMULA I

wherein:

$n$  is 0, 1, 2, or 3


the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds;

$R$ , and  $R'$  are independently selected from hydrogen, alkyl, aryl,  $-OH$ ,  $-OR''$ ,  $-SH$ ,  $-SR''$ ,  $-NH_2$ ,  $-NHR''$ ,  $=O$ ,  $=NH$ ,  $=NR''$ ;

$R''$  is independently selected from alkyl, aryl.

16.- A method of treating chronic neurodegenerative conditions including dementias such as Alzheimer's disease, Parkinson's disease, progressive supranuclear palsy, subacute sclerosing panencephalitic parkinsonism, postencephalitic parkinsonism, pugilistic encephalitis, guam parkinsonism-dementia complex, taupathies such as Pick's disease, corticobasal degeneration, supranuclear palsy, etc, frontotemporal dementia, Huntington's disease, AIDS associated dementia, amyotrophic lateral sclerosis, multiple sclerosis, , diabetes, especially diabetes type II, and conditions associated with diabetes, neurotraumatic diseases such as acute stroke, mood disorders such as schizophrenia and bipolar disorders, promotion of functional recovery post stroke, cerebral bleeding (for example, due to solitary cerebral amyloid angiopathy), hair loss, obesity, atherosclerotic cardiovascular disease, hypertension, polycystic ovary syndrome, syndrome X, ischaemia, traumatic brain injury, cancer, leukopenia, Down's syndrome, Lewy body disease, cancer and hyperproliferative diseases as hyperplasias, metaplasias, displasias and

immunodeficiency, psoriasis, arteriosclerosis or restenosis; and inflammation and chronic inflammatory processes, which comprises administering a compound of formula I:



FORMULA I

wherein:

n is 0, 1, 2, or 3

the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds;

R, and R' are independently selected from hydrogen, alkyl, aryl, -OH, -OR'', -SH, -SR'', -NH<sub>2</sub>, -NHR'', =O, =NH, =NR'';

R'' is independently selected from alkyl, aryl.